Biophage advertises PDS biosensor in Paris
2007-06-27 10:12 ET - News Release
Dr. Rosemonde Mandeville reports
BIOPHAGE ANNOUNCES COMMERCIAL LAUNCH OF ITS PDS(R) BIOSENSOR AT NANOTOXICITY 2007 TRADE SHOW IN PARIS; BIOSENSOR OFFERS SAFER AND MORE RELIABLE DETECTION METHOD AS AN ALTERNATIVE TO ANIMAL TOXICITY TESTING
Biophage Pharma Inc.'s PDS biosensor will make its commercial debut today at the Nanotoxicity 2007 trade show in Paris, France. This product represents the first of many innovative biosensors in development by the company's biosensor division. Biophage president and chief executive officer Dr. Rosemonde Mandeville will make a presentation on the PDS technology platform and the targeted markets for this biosensor, which was designed for the rapid detection of toxicity (predictive toxicity) of metals and nanoparticles.
The global demand for biosensors capable of rapidly detecting the toxic effect of metals or nanoparticles on living human cells is exploding. According to a recent BBC technical market research report, the United States in vitro toxicity testing (predictive toxicity) market had a value of $765-million in 2006 and will double by 2011, reaching $1.5-billion. Biophage is well positioned to capitalize on this rapidly expanding market by offering companies and research laboratories a novel and efficient biosensor that can rapidly screen large numbers of compounds for cell toxicity.
The PDS biosensor allows for the rapid and simultaneous screening of a large number of toxic compounds, metals and nanoparticles and determines their relative level of toxicity. It can also identify important parameters that determine toxicity levels at various stages of development and manufacturing, allowing companies to explore different strategies to circumvent potential toxic effects or mitigate the risk to humans, animals and the environment. The company's targeted clients are government and regulatory agencies, research laboratories, and environmental investigators in the biopharmaceutical, agricultural, cosmetics and probiotics fields.
"After many years of research and development, we are extremely pleased to have reached this important commercial milestone. I would like to congratulate our PDS biosensor development team who worked tirelessly to achieve our projected 2007 Q2 completion date, particularly Dr. Beatrice Allain (research and development director)," stated Dr. Mandeville, president and chief executive officer of Biophage Pharma. "This versatile biosensor provides a user-friendly, rapid and safer, in vitro toxicological first screening detection method. It represents a viable, cost-effective alternative for toxicity testing, and at the same time, offers customers a 'politically correct' solution which addresses the controversial issue of animal testing," continued Dr. Mandeville.
